[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
September 2015

Pricing and Value of Cancer Drugs

Author Affiliations
  • 1Pharmaceutical Research and Manufacturers of America, Washington, DC
JAMA Oncol. 2015;1(6):841-842. doi:10.1001/jamaoncol.2015.1962

To the Editor Mailankody and Prasad1 identify many important cancer treatments approved by the Food and Drug Administration. However, by failing to account for the complex and variable ways progress occurs, as well as the role of discounts in market-based pricing, the analysis does not provide enough information to correlate clinical value and price.